APRE
Aprea Therapeutics, Inc. [APRE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
APRE Stock Summary
Top 10 Correlated ETFs
APRE
Top 10 Correlated Stocks
APRE
In the News
APRE Financial details
Company Rating
-
Market Cap
31.01M
Income
-14.06M
Revenue
583.23K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
7
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-0.19
Forward P/E
-
PEG
0.02
P/S
-
P/B
1.15
P/C
-
P/FCF
-1.87
Quick Ratio
6.09
Current Ratio
6.15
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.92
EPS next Y
-
EPS next Q
-
EPS this Y
-99.85%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-95.59%
EPS Q/Q
6.98%
-
-
-
-
SMA20
-9.68%
SMA50
-33.33%
SMA100
-46.5%
Inst Own
-
Inst Trans
-
ROA
-471%
ROE
-507%
ROC
-0.67%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.78-8.847
52W High
-90.45%
52W Low
-61.8%
RSI
26.89
Rel Volume
1.17
Avg Volume
35.48K
Volume
41.56K
Perf Week
-14.15%
Perf Month
-18.27%
Perf Quarter
-53.41%
Perf Half Y
-59.36%
-
-
-
-
Beta
1.05453
-
-
Volatility
0.03%, 0.05%
Prev Close
-7.83%
Price
0.7641
Change
-4.49%
Company Profile
- Volume Average 35.48K
- Market Capitalization 31.01M
- Employee 7
- CEO Dr. Oren Gilad Ph.D.
- Headquarters Boston,MA,US
- IPO Date 2019-10-03
-
Website
https://atrinpharma.com 
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
